<p>TELA Bio（納斯達克代碼：TELA - 獲取免費報告）預計將在 2026 年 5 月 12 日星期二市場收盤後發佈其 2026 年第一季度財報。分析師預計該公司將宣佈每股收益為（$0.14），季度收入為 1859.70 萬美元。有興趣的人士可以查看公司即將發佈的 2026 年第一季度財報的信息，以獲取關於定於 2026 年 5 月 12 日下午 4:30（東部時間）的電話會議的最新詳情。</p>
<p>TELA Bio（納斯達克代碼：TELA - 獲取免費報告）最近一次發佈季度財報是在 3 月 24 日星期二。該公司報告的季度每股收益為（$0.16），超出分析師一致預期的（$0.18）$0.02。該季度的收入為 2087 萬美元，而分析師預期為 2104 萬美元。TELA Bio 的股本回報率為負 433.58%，淨利潤率為負 48.37%。平均而言，分析師預計 TELA Bio 在當前財年將發佈每股收益為-$1，在下一個財年將發佈每股收益為$0。</p>
<h2>TELA Bio 股票表現</h2>
<p>在週二的交易中，納斯達克 TELA 上漲了$0.10，達到了$1.19。該公司的股票交易量為 332,411 股，而其平均交易量為 196,760 股。該公司的市值為 5324 萬美元，市盈率為-1.43，貝塔值為 1.30。TELA Bio 的 52 周低點為$0.50，52 周高點為$2.20。該公司的速動比率為 3.59，流動比率為 4.20，債務與股本比率為 8.82。該公司的 50 日移動平均價格為$0.73，200 日移動平均價格為$0.98。</p>
<h2>分析師評級調整</h2>
<p>TELA 最近受到了一些分析師報告的關注。Piper Sandler 在 3 月 25 日星期三的報告中將 TELA Bio 的目標價從$1.25 下調至$1.00，並對該公司給予了 “中性” 評級。Weiss Ratings 在 4 月 21 日星期二的研究報告中重申了對 TELA Bio 股票的 “賣出（e+）” 評級。Canaccord Genuity Group 在 3 月 25 日星期三的研究報告中將 TELA Bio 的目標價從$4.00 下調至$2.00，並對該股票給予了 “買入” 評級。Citizens Jmp 在 3 月 27 日星期五的研究報告中將 TELA Bio 的目標價從$5.00 下調至$3.00，並對該公司給予了 “市場表現優於大盤” 的評級。最後，Lake Street Capital 在 3 月 25 日星期三的研究報告中將 TELA Bio 的目標價從$3.00 下調至$2.00，並對該公司給予了 “買入” 評級。三位股票研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “持有”，共識目標價為$2.20。</p>
<p><strong>查看我們對 TELA 的最新分析</strong></p>
<h2>TELA Bio 的機構交易</h2>
<p>一些大型投資者最近增加或減少了對 TELA 的持股。Citadel Advisors LLC 在第三季度將其在 TELA Bio 的持股比例提高了 161.3%。Citadel Advisors LLC 現在擁有 35,281 股該公司的股票，價值 53,000 美元，此前在上個季度增持了 21,781 股。XTX Topco Ltd 在第四季度收購了 TELA Bio 的新股份，價值約 48,000 美元。Renaissance Technologies LLC 在第四季度將其在 TELA Bio 的持股比例提高了 101.4%。Renaissance Technologies LLC 現在擁有 128,700 股該公司的股票，價值 152,000 美元，此前在該期間增持了 64,800 股。最後，Susquehanna International Group LLP 在第三季度將其在 TELA Bio 的持股比例提高了 551.2%。Susquehanna International Group LLP 現在擁有 85,763 股該公司的股票，價值 128,000 美元，此前在上個季度增持了 72,594 股。機構投資者和對沖基金持有該公司 94.35% 的股票。</p>
<h2>TELA Bio 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>TELA Bio, Inc（納斯達克代碼：TELA）是一家總部位於賓夕法尼亞州馬爾文的商業階段醫療技術公司。該公司專注於開發、製造和商業化再生醫學和先進軟組織修復解決方案。通過整合專有生物材料和加工技術，TELA Bio 旨在提供支持身體自然癒合過程的產品，用於傷口閉合、疝氣修復、重建手術和其他外科專業。</p>
<p>該公司的產品組合包括無細胞真皮基質、止血劑和組織支架系統。</p>
<h2>特色文章</h2>
<ul>
<li>五隻我們認為比 TELA Bio 更好的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVMQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVMQQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 TELA Bio 嗎？</h2>
<p>在你考慮 TELA Bio 之前，你需要聽聽這個。</p>
<p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 TELA Bio 並不在名單上。</p>
<p>雖然 TELA Bio 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

TELA

<p>TELA Bio（納斯達克代碼：TELA）計劃於 5 月 12 日發佈 2026 年第一季度財報，分析師預測每股虧損 0.14 美元，收入為 1860 萬美元。該公司此前報告 2025 年第一季度每股虧損 0.16 美元，超出預期。TELA 的股票目前交易價格為 1.19 美元，市值為 5324 萬美元。最近的分析師評級顯示買入、持有和賣出的推薦混合，平均目標價格為 2.20 美元。機構投資者持有 TELA 94.35% 的股份，顯示出對該公司的強烈興趣</p>

<p>TELA Bio (NASDAQ:TELA - Get Free Report) is expected to issue its Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.14) per share and revenue of $18.5970 million for the quarter. Interested persons may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:30 PM ET.</p>
<div class="lb-trans"><p>TELA Bio（納斯達克代碼：TELA - 獲取免費報告）預計將在 2026 年 5 月 12 日星期二市場收盤後發佈其 2026 年第一季度財報。分析師預計該公司將宣佈每股收益為（$0.14），季度收入為 1859.70 萬美元。有興趣的人士可以查看公司即將發佈的 2026 年第一季度財報的信息，以獲取關於定於 2026 年 5 月 12 日下午 4:30（東部時間）的電話會議的最新詳情。</p>
</div><p>TELA Bio (NASDAQ:TELA - Get Free Report) last posted its quarterly earnings data on Tuesday, March 24th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.18) by $0.02. The business had revenue of $20.87 million for the quarter, compared to analyst estimates of $21.04 million. TELA Bio had a negative return on equity of 433.58% and a negative net margin of 48.37%. On average, analysts expect TELA Bio to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>TELA Bio（納斯達克代碼：TELA - 獲取免費報告）最近一次發佈季度財報是在 3 月 24 日星期二。該公司報告的季度每股收益為（$0.16），超出分析師一致預期的（$0.18）$0.02。該季度的收入為 2087 萬美元，而分析師預期為 2104 萬美元。TELA Bio 的股本回報率為負 433.58%，淨利潤率為負 48.37%。平均而言，分析師預計 TELA Bio 在當前財年將發佈每股收益為-$1，在下一個財年將發佈每股收益為$0。</p>
</div><h2>TELA Bio Stock Performance</h2>
<div class="lb-trans"><h2>TELA Bio 股票表現</h2>
</div><p>NASDAQ TELA traded up $0.10 during trading on Tuesday, hitting $1.19. The company's stock had a trading volume of 332,411 shares, compared to its average volume of 196,760. The firm has a market cap of $53.24 million, a P/E ratio of -1.43 and a beta of 1.30. TELA Bio has a 52 week low of $0.50 and a 52 week high of $2.20. The company has a quick ratio of 3.59, a current ratio of 4.20 and a debt-to-equity ratio of 8.82. The firm has a 50 day moving average price of $0.73 and a 200 day moving average price of $0.98.</p>
<div class="lb-trans"><p>在週二的交易中，納斯達克 TELA 上漲了$0.10，達到了$1.19。該公司的股票交易量為 332,411 股，而其平均交易量為 196,760 股。該公司的市值為 5324 萬美元，市盈率為-1.43，貝塔值為 1.30。TELA Bio 的 52 周低點為$0.50，52 周高點為$2.20。該公司的速動比率為 3.59，流動比率為 4.20，債務與股本比率為 8.82。該公司的 50 日移動平均價格為$0.73，200 日移動平均價格為$0.98。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級調整</h2>
</div><p>TELA has been the subject of a number of recent analyst reports. Piper Sandler dropped their price target on TELA Bio from $1.25 to $1.00 and set a &#34;neutral&#34; rating for the company in a report on Wednesday, March 25th. Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of TELA Bio in a research note on Tuesday, April 21st. Canaccord Genuity Group reduced their price target on shares of TELA Bio from $4.00 to $2.00 and set a &#34;buy&#34; rating on the stock in a research report on Wednesday, March 25th. Citizens Jmp lowered their price objective on shares of TELA Bio from $5.00 to $3.00 and set a &#34;market outperform&#34; rating for the company in a research report on Friday, March 27th. Finally, Lake Street Capital decreased their target price on TELA Bio from $3.00 to $2.00 and set a &#34;buy&#34; rating for the company in a research note on Wednesday, March 25th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of &#34;Hold&#34; and a consensus target price of $2.20.</p>
<div class="lb-trans"><p>TELA 最近受到了一些分析師報告的關注。Piper Sandler 在 3 月 25 日星期三的報告中將 TELA Bio 的目標價從$1.25 下調至$1.00，並對該公司給予了 “中性” 評級。Weiss Ratings 在 4 月 21 日星期二的研究報告中重申了對 TELA Bio 股票的 “賣出（e+）” 評級。Canaccord Genuity Group 在 3 月 25 日星期三的研究報告中將 TELA Bio 的目標價從$4.00 下調至$2.00，並對該股票給予了 “買入” 評級。Citizens Jmp 在 3 月 27 日星期五的研究報告中將 TELA Bio 的目標價從$5.00 下調至$3.00，並對該公司給予了 “市場表現優於大盤” 的評級。最後，Lake Street Capital 在 3 月 25 日星期三的研究報告中將 TELA Bio 的目標價從$3.00 下調至$2.00，並對該公司給予了 “買入” 評級。三位股票研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “持有”，共識目標價為$2.20。</p>
</div><p><strong>View Our Latest Analysis on TELA</strong></p>
<div class="lb-trans"><p><strong>查看我們對 TELA 的最新分析</strong></p>
</div><h2>Institutional Trading of TELA Bio</h2>
<div class="lb-trans"><h2>TELA Bio 的機構交易</h2>
</div><p>A number of large investors have recently added to or reduced their stakes in TELA. Citadel Advisors LLC lifted its position in TELA Bio by 161.3% during the third quarter. Citadel Advisors LLC now owns 35,281 shares of the company's stock worth $53,000 after acquiring an additional 21,781 shares during the last quarter. XTX Topco Ltd acquired a new stake in TELA Bio during the 4th quarter worth approximately $48,000. Renaissance Technologies LLC boosted its stake in TELA Bio by 101.4% in the 4th quarter. Renaissance Technologies LLC now owns 128,700 shares of the company's stock valued at $152,000 after purchasing an additional 64,800 shares during the period. Finally, Susquehanna International Group LLP grew its holdings in TELA Bio by 551.2% in the 3rd quarter. Susquehanna International Group LLP now owns 85,763 shares of the company's stock valued at $128,000 after buying an additional 72,594 shares in the last quarter. Institutional investors and hedge funds own 94.35% of the company's stock.</p>
<div class="lb-trans"><p>一些大型投資者最近增加或減少了對 TELA 的持股。Citadel Advisors LLC 在第三季度將其在 TELA Bio 的持股比例提高了 161.3%。Citadel Advisors LLC 現在擁有 35,281 股該公司的股票，價值 53,000 美元，此前在上個季度增持了 21,781 股。XTX Topco Ltd 在第四季度收購了 TELA Bio 的新股份，價值約 48,000 美元。Renaissance Technologies LLC 在第四季度將其在 TELA Bio 的持股比例提高了 101.4%。Renaissance Technologies LLC 現在擁有 128,700 股該公司的股票，價值 152,000 美元，此前在該期間增持了 64,800 股。最後，Susquehanna International Group LLP 在第三季度將其在 TELA Bio 的持股比例提高了 551.2%。Susquehanna International Group LLP 現在擁有 85,763 股該公司的股票，價值 128,000 美元，此前在上個季度增持了 72,594 股。機構投資者和對沖基金持有該公司 94.35% 的股票。</p>
</div><h2>TELA Bio Company Profile</h2>
<div class="lb-trans"><h2>TELA Bio 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>TELA Bio, Inc NASDAQ: TELA is a commercial‐stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body's natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.</p>
<div class="lb-trans"><p>TELA Bio, Inc（納斯達克代碼：TELA）是一家總部位於賓夕法尼亞州馬爾文的商業階段醫療技術公司。該公司專注於開發、製造和商業化再生醫學和先進軟組織修復解決方案。通過整合專有生物材料和加工技術，TELA Bio 旨在提供支持身體自然癒合過程的產品，用於傷口閉合、疝氣修復、重建手術和其他外科專業。</p>
</div><p>The company's product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems.</p>
<div class="lb-trans"><p>該公司的產品組合包括無細胞真皮基質、止血劑和組織支架系統。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than TELA Bio</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 TELA Bio 更好的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVMQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=TELA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in TELA Bio Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 TELA Bio 嗎？</h2>
</div><p>Before you consider TELA Bio, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 TELA Bio 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TELA Bio wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 TELA Bio 並不在名單上。</p>
</div><p>While TELA Bio currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 TELA Bio 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

TELA Bio（TELA）預計將在週二發佈財報